Postpartum Depression Therapeutics Market Size in the 7MM was ~USD 260 Million in 2023, is expected to grow by 2034, and estimates DelveInsight
DelveInsight's " Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Explore the intricate details of the Postpartum Depression Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Postpartum Depression Market Forecast. Click here to stay ahead in healthcare innovation @ Postpartum Depression Market Size
Key Takeaways from the Postpartum Depression Market Research Report
Among the seven major countries, the total Postpartum Depression diagnosed prevalence cases were ~1,310,000, in 2023.
In EU4 and the UK, the total Postpartum Depression diagnosed prevalence cases were ~4,60,000 in 2023.
In the seven major market, the United States accounted for the highest number of Postpartum Depression diagnosed cases (~720,000), followed by the UK, in 2023.
In Japan, the total Postpartum Depression diagnosed prevalent cases were ~126,000 in 2023.
The leading Postpartum Depression Companies such as Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
Promising Postpartum Depression Pipeline Therapies such as SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296, and others.
Discover which therapies are expected to grab the Postpartum Depression Market Share @ Postpartum Depression Market Outlook
• Total Postpartum Depression Diagnosed Prevalent Population of Maternal
Download the report to understand which factors are driving Postpartum Depression epidemiology trends @ Postpartum Depression Prevalence
Postpartum Depression Marketed Therapies
Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.
ZULRESSO: Sage Therapeutics
ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults. The mechanism of action of brexanolone in treating PPD in adults is related to its positive allosteric modulation of GABAA receptors. Brexanolone potentiated GABA-mediated currents from recombinant human GABAA receptors in mammalian cells expressing α1β2γ2 receptor subunits, α4β3δ receptor subunits, and α6β3δ receptor subunits.
Postpartum Depression Emerging Therapies
Ganaxolone: Marinus Pharmaceuticals
Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits antiseizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone's potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone.
Unlock insights into the Postpartum Depression Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Postpartum Depression Market Forecast. Click here @ Postpartum Depression Market Drivers and Barriers
Postpartum Depression Market Outlook
Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life.
Scope of the Postpartum Depression Market Report
Coverage- 7MM
Study Period- 2020-2034
Postpartum Depression Companies- Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
Postpartum Depression Pipeline Therapies- SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296, and others.
Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Barriers
Postpartum Depression Market Access and Reimbursement, and Unmet Needs
Gain a strategic edge in the Postpartum Depression Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Postpartum Depression Market Forecast. Click here to lead in advancements @ Postpartum Depression Clinical Trials Assessment
Table of Content
1. Key Insights
2. Report Introduction
3. Postpartum Depression Market Overview at a Glance
4. Executive Summary of Postpartum depression (PPD)
5. Key events
6. Disease Background and Overview
7. Treatment and Management
8. Methodology
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. Postpartum Depression (PPD): Seven Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 hours ago
- Globe and Mail
Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Graft vs Host Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Graft vs Host Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' Graft vs Host Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graft vs Host Disease Market. The Graft vs Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Graft vs Host Disease Pipeline Report: Companies across the globe are diligently working toward developing novel Graft vs Host Disease treatment therapies with a considerable amount of success over the years. Graft vs Host Disease companies working in the treatment market are Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others, are developing therapies for the Graft vs Host Disease treatment Emerging Graft vs Host Disease therapies in the different phases of clinical trials are- ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others are expected to have a significant impact on the Graft vs Host Disease market in the coming years. In April 2025, The California Institute for Regenerative Medicine (CIRM) has granted $8 million to biotech firm Tr1X to advance its Phase I/IIa clinical trial of TRX103. This therapy aims to prevent graft-versus-host disease (GvHD) in blood cancer patients receiving mismatched stem cell transplants. TRX103 is an allogeneic, engineered type 1 regulatory (Tr1) Treg cell therapy designed to reduce transplant-related complications and improve patient outcomes. In March 2025, Orca Bio's investigational T-cell immunotherapy for blood cancers significantly improved outcomes, more than doubling the rate of patients who remained free from moderate-to-severe chronic graft-versus-host disease (GvHD). According to results from the Phase III Precision-T trial (NCT05316701), 78% of patients treated with Orca-T (TRGFT-201), the company's lead allogeneic T-cell therapy, were GvHD-free after one year, compared to only 38% in the group receiving standard allogeneic stem cell transplants. In January 2025, MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech company specializing in Microbiome Ecosystem Therapies™ (MET) aimed at improving survival outcomes in cancer patients through immune system modulation, has announced positive topline results from its pivotal Phase 3 ARES trial. This single-arm, open-label, multicenter study conducted across Europe assessed the safety and efficacy of MaaT013 in patients with acute Graft-versus-Host Disease involving the gastrointestinal tract (GI-aGvHD) who are in third-line treatment — meaning they are resistant to steroids and either refractory or intolerant to ruxolitinib. The trial successfully achieved its primary endpoint, with a 28-day gastrointestinal overall response rate (GI-ORR) of 62%, significantly surpassing the expected rate of 38%. These outcomes, evaluated by an Independent Review Committee (IRC), exceeded the predefined efficacy threshold and underscore the strong clinical potential of MaaT013 in treating third-line GI-aGvHD. In December 2024, The FDA has granted approval to Mesoblast's allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, remestemcel-L, for treating steroid-refractory acute graft versus host disease (GvHD) in pediatric patients aged two months and older. Significantly, this marks the first FDA-approved MSC-based therapy. The treatment will be commercially available under the brand name Ryoncil. Graft vs Host Disease Overview Graft versus Host Disease (GvHD) is a medical condition that can occur after a stem cell or bone marrow transplant, where the donor's immune cells (graft) recognize the recipient's body (host) as foreign and attack it. GvHD commonly affects the skin, liver, and gastrointestinal tract. It is classified into acute and chronic forms, with symptoms ranging from mild rashes and diarrhea to severe organ damage. Management typically involves immunosuppressive therapies to reduce the immune response. Emerging Graft vs Host Disease Drugs Under Different Phases of Clinical Development Include: ABSK021: Abbisko Therapeutics SYN-004: Theriva Biologics SER-155: Seres Therapeutics CB103: Cellestia Biotech Glasdegib: Pfizer TQ 05105: Chia Tai Tianqing Pharmaceutical RGI-2001: Regimmune Corporation Axatilimab: Syndax Pharmaceuticals MaaT013: MaaT Pharma MC 0518: Medac Itolizumab: Equillium Elranatamab: Pfizer Felzartamab: Janssen Pharmaceutical T-Guard: Xenikos MaaT013: MaaT Pharma Axatilimab: Syndax Pharmaceuticals TQ 05105: Chia Tai Tianqing Pharmaceutical Group Graft vs Host Disease Route of Administration Graft vs Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Intravenous Subcutaneous Graft vs Host Disease Molecule Type Graft vs Host Disease Products have been categorized under various Molecule types, such as Small molecule Cell Therapy Peptides Polymer Small molecule Gene therapy Graft vs Host Disease Pipeline Therapeutics Assessment Graft vs Host Disease Assessment by Product Type Graft vs Host Disease By Stage and Product Type Graft vs Host Disease Assessment by Route of Administration Graft vs Host Disease By Stage and Route of Administration Graft vs Host Disease Assessment by Molecule Type Graft vs Host Disease by Stage and Molecule Type DelveInsight's Graft vs Host Disease Report covers around 50+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Graft vs Host Disease product details are provided in the report. Download the Graft vs Host Disease pipeline report to learn more about the emerging Graft vs Host Disease therapies Some of the key companies in the Graft vs Host Disease Therapeutics Market include: Key companies developing therapies for Graft vs Host Disease are - Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology, AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others. Graft vs Host Disease Pipeline Analysis: The Graft vs Host Disease pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Graft vs Host Disease with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft vs Host Disease Treatment. Graft vs Host Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Graft vs Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft vs Host Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Graft vs Host Disease Pipeline Market Drivers Increase in the number of patients suffering from chronic GvHD, robust Pipeline of GvHD are some of the important factors that are fueling the Graft vs Host Disease Market. Graft vs Host Disease Pipeline Market Barriers However, high cost of treatment, recognizing the limitations of currently available aGVHD therapies and other factors are creating obstacles in the Graft vs Host Disease Market growth. Scope of Graft vs Host Disease Pipeline Drug Insight Coverage: Global Key Graft vs Host Disease Companies: Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others Key Graft vs Host Disease Therapies: ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others Graft vs Host Disease Therapeutic Assessment: Graft vs Host Disease current marketed and Graft vs Host Disease emerging therapies Graft vs Host Disease Market Dynamics: Graft vs Host Disease market drivers and Graft vs Host Disease market barriers Table of Contents 1. Graft vs Host Disease Report Introduction 2. Graft vs Host Disease Executive Summary 3. Graft vs Host Disease Overview 4. Graft vs Host Disease- Analytical Perspective In-depth Commercial Assessment 5. Graft vs Host Disease Pipeline Therapeutics 6. Graft vs Host Disease Late Stage Products (Phase II/III) 7. Graft vs Host Disease Mid Stage Products (Phase II) 8. Graft vs Host Disease Early Stage Products (Phase I) 9. Graft vs Host Disease Preclinical Stage Products 10. Graft vs Host Disease Therapeutics Assessment 11. Graft vs Host Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Graft vs Host Disease Key Companies 14. Graft vs Host Disease Key Products 15. Graft vs Host Disease Unmet Needs 16 . Graft vs Host Disease Market Drivers and Barriers 17. Graft vs Host Disease Future Perspectives and Conclusion 18. Graft vs Host Disease Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
a day ago
- Globe and Mail
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
With the end of the pandemic, sales of Pfizer 's PFE COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer's non-COVID operational revenues improved in 2024 and so far in 2025, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Year 2023 was a record year for Pfizer in terms of new drug approvals. It received nine new medicine/vaccine approvals in 2023 that have begun to contribute to top-line growth. In 2024, it gained approval for some interesting new products like two gene therapies for hemophilia, Hympavzi (marstacimab) and Beqvez/Durveqtix (fidanacogene elaparvovec). The December 2023 acquisition of Seagen strengthened Pfizer's position in oncology by adding four antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer's revenues in 2024 and the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline. Pfizer faces its share of challenges, including declining sales of its COVID-19 products, U.S. Medicare Part D headwinds, the upcoming loss of exclusivity cliff, uncertainties around tariffs and a volatile macro environment. However, its new products/late-stage pipeline candidates and newly acquired products, including those acquired from Seagen, position it strongly for operational growth in 2025 and beyond. Competition in the Oncology Space Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Bristol-Myers BMY. For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. PFE's Price Performance, Valuation and Estimates Pfizer's stock has declined 4.4% so far this year compared with an increase of 3.1% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 7.97 forward earnings, lower than 15.54 for the industry and the stock's 5-year mean of 10.91. The Zacks Consensus Estimate for 2025 earnings has risen from $2.98 per share to $3.06 per share, while that for 2026 has gone up from $3.00 to $3.09 per share over the past 60 days. Pfizer has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Globe and Mail
2 days ago
- Globe and Mail
Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5%
Dividend income offers a great way to strengthen your overall financial position. It can potentially make you less dependent on the income you earn from a job, maybe even allowing you to work less or retire earlier than planned. Money doesn't buy happiness, but being less dependent on work to fund your lifestyle could be a contributor to a happier, less stressful life. A great way to build up dividend income is to invest in high-yielding dividend stocks that also happen to be lower-risk investments. Pfizer (NYSE: PFE), Realty Income (NYSE: O), and Bank of Nova Scotia (NYSE: BNS) are three attractive investments that you'll want to consider if you want to create a strong portfolio of income-generating stocks. Pfizer If you're looking for a high-yielding stock to hold for the long term, Pfizer is one you'll want to strongly consider. At 7.4%, its yield right now is more than five times what you'd get with the average stock on the S&P 500, which pays about 1.3%. Pfizer's stock is trading down more than 10% this year (as of the end of last week), as it can't seem to catch a break. While its valuation is modest -- it trades at 17 times its trailing earnings -- concerns about healthcare reform and the company's future growth prospects have made investors uneasy about the business and investing in it. But the healthcare company is still doing well and is on track to hit its guidance, which calls for revenue between $61 billion and $64 billion this year (comparable to how it did last year). It is also slashing costs to improve its bottom line. And it has been less than two years since it acquired oncology company Seagen, which may unlock more long-term growth for Pfizer in the future. Last year, the company also obtained approval from regulators for its first gene therapy in the U.S. -- Beqvez, a treatment for a genetic bleeding disorder. There's some uncertainty and risk with Pfizer, but there are opportunities as well. And at such a modest valuation, now can be an excellent time to add it to your portfolio. Pfizer has been a big name in healthcare for decades, and I don't think that's likely to change anytime soon. Realty Income One dividend stock I think all income investors should consider owning is Realty Income. This is a real estate investment trust (REIT) that not only offers a high yield of 5.8%, but it also pays a dividend every month. There's no need to wait around for multiple months, as is the case with other dividend stocks; with Realty Income, you're getting a much more regular stream of cash flow. The REIT has a diverse mix of tenants, which makes it an ideal option for long-term investors. It's diversified across industries and geographies, with more than 1,500 clients across 91 industries. The dividend remains well supported -- the REIT reported funds from operations (FFO) per share of $1.05 during the first three months of the year (versus $0.94 a year ago). That averages out to $0.35 per share per month, which is higher than the rate of its monthly dividend of $0.2685. REITs use FFO to assess how much they can afford to pay in dividends, and with Realty Income's financials looking solid, there aren't any significant risks with its payout. Share prices of Realty Income are up 5% this year, and this can be a great income-generating investment to add to your portfolio for the long haul. Bank of Nova Scotia Rounding out this list of high-yielding dividend stocks is Canada-based Bank of Nova Scotia, also known as Scotiabank. At around 6%, that's a high payout for a top bank stock that is known for long-term stability. It declared its first dividend back in 1833 and has continued making regular payments since then. The bank increased its provision for credit losses in its most recent quarter, in a sign of growing concern about macroeconomic conditions. Scotiabank's net income totaled over $2 billion Canadian dollars for the period ending April 30, which was nearly identical to its bottom line in the prior-year period. There are concerns about how the Canadian economy may perform in the near future due to tariffs, but in the grand scheme of things, that may prove to be a short-term concern for investors who are willing to hang on for years. Scotiabank's impressive track record and resilience over the years should inspire some confidence in the business. The bank stock has increased its dividend by more than 22% in four years and can be an excellent option to hang on to for the long term. Not only can you collect a high yield today, but the dividend income you get from this investment can rise over the years. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor 's total average return is996% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
